Yes, give the ticagrelor 180 mg loading dose before starting 90 mg twice daily maintenance, even though the patient is already on clopidogrel.
For NSTEMI patients managed conservatively (non-invasively), you should administer a 180 mg loading dose of ticagrelor followed by 90 mg twice daily maintenance starting 6-12 hours after the load, regardless of prior clopidogrel therapy. 1, 2
Rationale for Loading Dose
The 2025 ACC/AHA guidelines explicitly recommend a 180 mg loading dose of ticagrelor for all NSTEMI patients (Table 7), with no distinction made for those already on clopidogrel 1. The FDA label similarly specifies initiating treatment with a 180 mg loading dose for ACS 2. This approach ensures:
- Rapid, predictable platelet inhibition within 2 hours, reaching optimal levels needed for acute thrombotic protection 3
- Overcoming any residual clopidogrel effect, which is less potent and more variable than ticagrelor
- Standardized dosing that was proven effective in the PLATO trial, which demonstrated ticagrelor's superiority over clopidogrel in reducing cardiovascular death, MI, and stroke 1
Addressing the Aspirin Allergy
This is a critical consideration. The patient cannot receive aspirin due to allergy, which creates a deviation from standard dual antiplatelet therapy. However:
- Ticagrelor monotherapy is still indicated as a P2Y12 inhibitor is recommended for all ACS patients to reduce MACE 1
- The guidelines state that a P2Y12 inhibitor should be administered "in addition to aspirin" when possible, but aspirin allergy is an absolute contraindication 1
- Consider this patient for P2Y12 inhibitor monotherapy, which recent evidence suggests may be reasonable in select circumstances, though this is primarily studied post-PCI 1
Practical Implementation
Step-by-step approach:
- Stop clopidogrel immediately - do not give another dose
- Administer ticagrelor 180 mg loading dose as soon as possible
- Wait 6-12 hours, then start ticagrelor 90 mg twice daily
- Continue for at least 12 months unless bleeding complications arise 1
- Monitor for dyspnea (occurs in ~14-21% of patients) - usually mild and resolves, but can lead to discontinuation 2
- Watch for bradyarrhythmias - ticagrelor can cause ventricular pauses and AV block 2
Common Pitfalls to Avoid
- Don't skip the loading dose thinking clopidogrel provides adequate coverage - research shows that switching from clopidogrel to ticagrelor without a load is feasible 4, but guidelines and FDA labeling mandate the load for ACS 1, 2
- Don't wait for clopidogrel to "wash out" - switch immediately as ticagrelor's superior potency will override clopidogrel's effects
- Don't attempt to substitute another antiplatelet for aspirin - the patient will be on ticagrelor monotherapy, which is acceptable given the aspirin allergy
- Don't discontinue ticagrelor abruptly if dyspnea develops - evaluate other causes first, as stopping increases risk of subsequent cardiovascular events 2
Conservative Management Context
Since the family declined invasive intervention, this patient represents a medically managed NSTEMI. The 2025 guidelines give ticagrelor a Class I, Level B-R recommendation for NSTEMI patients regardless of invasive vs. conservative strategy 1. Ticagrelor has demonstrated benefit in both invasively and conservatively managed patients, making it appropriate here despite the non-invasive approach.